Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Antares Vision SpA ( (IT:AV) ) is now available.
Antares Vision has updated its stand‑alone industrial plan after its board reviewed preliminary 2025 figures, which indicate revenues of about €204 million, an adjusted EBITDA margin of around 16% and leverage of roughly 2.4 times adjusted EBITDA, broadly in line with earlier guidance. The revision reflects weaker order intake in its Life Science business, persistent macro and geopolitical uncertainty, and the support of government‑linked L5 projects, prompting the company to replace its prior 2025–27 targets with a more moderate 2025–28 mid‑single‑digit revenue CAGR, while aiming to lift adjusted EBITDA margins to 19–20% and reduce leverage to below one times by 2028, underscoring continued financial solidity and ongoing investment in innovation and digitalization despite a volatile environment.
The new plan indicates that previously announced growth targets are no longer current, signaling a recalibration of expectations in response to sector headwinds but also highlighting the contribution of new government projects to future growth. Management emphasizes that the group’s capital structure remains robust and that it intends to maintain a balanced, sustainable approach as it pursues long‑term objectives, which may reassure investors about the company’s resilience and strategic focus in a challenging market.
The most recent analyst rating on (IT:AV) stock is a Hold with a EUR5.00 price target. To see the full list of analyst forecasts on Antares Vision SpA stock, see the IT:AV Stock Forecast page.
More about Antares Vision SpA
Antares Vision Group is an Italian multinational listed on Euronext STAR Milan that provides technologies for quality control, traceability and integrated data management to ensure product safety and supply chain transparency. It serves the Life Science, cosmetics and fast‑moving consumer goods sectors worldwide, leading the pharmaceutical traceability market, supplying over half of the top 20 global pharma multinationals and several government authorities, with operations in more than 60 countries and about 1,200 employees.
Average Trading Volume: 117,084
Technical Sentiment Signal: Hold
Current Market Cap: €360.5M
Learn more about AV stock on TipRanks’ Stock Analysis page.